UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
June 30, 2020 09:05 ET
|
Galectin Therapeutics Inc.
Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy Belapectin has previously shown ability to prevent the development of esophageal varices in this...
Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
June 30, 2020 08:00 ET
|
Galectin Therapeutics Inc.
Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy Belapectin has previously shown ability to prevent the development of esophageal varices in this...
INmune Bio to Present at BIO CEO & Investor Conference
February 06, 2019 09:00 ET
|
INmune Bio, Inc.
LA JOLLA, CA, Feb. 06, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (Nasdaq: INMB) (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s...
Interpace Diagnostics to Attend BIO CEO & Investor Conference in New York City
February 04, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) today announced the Company will attend the 21st BIO CEO & Investor Conference being held in New...
Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure
January 15, 2019 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its largest...
Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit
November 19, 2018 09:19 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update
November 13, 2018 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference
October 15, 2018 10:22 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will...
Galectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference
October 15, 2018 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will...
Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial
September 20, 2018 08:00 ET
|
Galectin Therapeutics Inc.
Combination immunotherapy of GR-MD-02 and KEYTRUDA for all cohorts reported shows an Objective Response Rate of 50% (seven of fourteen patients). The published response rate of KEYTRUDA alone is 33%...